Pembrolizumab

Description	Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. In addition to Melanoma and Lung carcinoma, pembrolizumab has also demonstrated efficacy in other advanced solid tumors and hematologic malignancies. Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer.
Pathways	Apoptosis Pathway
Targets	PD 1/PD L1

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.